Rafferty Asset Management, LLC Karuna Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$161.01 - $317.85 $751,433 - $1.48 Million	-4,667 Reduced 9.65%	43,693 $13.8 Million
Q3 2023 Nov 13, 2023	BUY	$164.66 - $218.08 $1.96 Million - $2.59 Million	11,883 Added 32.58%	48,360 $8.18 Million
Q2 2023 Aug 11, 2023	SELL	$176.32 - $240.22 $260,600 - $355,045	-1,478 Reduced 3.89%	36,477 $7.91 Million
Q1 2023 May 11, 2023	SELL	$161.33 - $204.36 $499,639 - $632,902	-3,097 Reduced 7.54%	37,955 $6.89 Million
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $2.53 Million - $3.13 Million	13,226 Added 47.53%	41,052 $8.07 Million
Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $1.2 Million - $2.7 Million	-9,732 Reduced 25.91%	27,826 $6.26 Million
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $1.35 Million - $2.07 Million	-14,416 Reduced 27.74%	37,558 $4.75 Million
Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $1.12 Million - $1.51 Million	11,371 Added 28.01%	51,974 $6.59 Million
Q4 2021 Feb 10, 2022	BUY	$110.64 - $159.4 $1.6 Million - $2.3 Million	14,433 Added 55.15%	40,603 $5.32 Million
Q3 2021 Nov 10, 2021	BUY	$101.2 - $125.87 $706,983 - $879,327	6,986 Added 36.42%	26,170 $3.2 Million
Q2 2021 Aug 10, 2021	SELL	$107.45 - $135.95 $935,889 - $1.18 Million	-8,710 Reduced 31.23%	19,184 $2.19 Million
Q1 2021 May 10, 2021	BUY	$95.46 - $133.08 $1.99 Million - $2.78 Million	20,859 Added 296.5%	27,894 $3.35 Million
Q4 2020 Feb 10, 2021	SELL	$75.23 - $109.23 $999,355 - $1.45 Million	-13,284 Reduced 65.38%	7,035 $715,000
Q3 2020 Nov 13, 2020	BUY	$71.31 - $109.74 $844,096 - $1.3 Million	11,837 Added 139.55%	20,319 $1.57 Million
Q2 2020 Aug 07, 2020	BUY	$62.14 - $117.21 $527,071 - $994,175	8,482 New	8,482 $945,000

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account